Table 1.
Baseline characteristics and prevalence of development of infectious complications
| Age – year | |
| Median | 54 |
| Interquartile range | 40–63 |
| Female sex – no. (%) | 44 (42) |
| Underlying cancer – no. (%) | |
| Acute leukaemia | 35 (33) |
| Lymphocytic | 8 (6) |
| Myelogenous | 26 (25) |
| Promyelocytic | 1 (1) |
| Lymphoma/Hodgkin's disease | 37 (35) |
| Hodgkin's disease | 6 (6) |
| Low-grade lymphoma | 3 (3) |
| Intermediate-grade lymphoma | 16 (15) |
| High-grade lymphoma | 12 (11) |
| Other haematological | 33 (31) |
| Febrile neutropenia – no. (%)* | 62 (53) |
| Documented infection – no. (%)* | 61 (52) |
| Bacteraemia – no. (%)* | 26 (22) |
| Severe infection – no. (%)* | 38 (32) |
*
Prevalence of febrile neutropenia, documented infection, bacteraemia and severe infection in the 117 chemotherapy cycles.